|
CD 40 CD 40L与血栓性疾病研究进展 |
| |
sp;al . CD 40L stabilizes arterialthrombi by a beta3 integrindependent mechamism[J ] . Nat Med , 2002 ,8 (3):247252.
[16] URBICH C ,DERNBACH E ,AICHER A , et al . CD 40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species[J].Circulation,2002,106 (8):981986.
[17] 徐邦牢,王蓉,贝春花等. 1 型糖尿病患者血清sCD 40L 测定的临床意义.中国热带医学2005,7(5):14321433.
[18] NIKOLAUS MARX, ARMIN IMHOF, JOHANNES FROEHLICH, et al . Effect of Rosiglitazone Treatment on Soluble CD 40L in Patients With Type 2 Diabetes and Coronary Artery Disease. Circulation. 2003,107:19541957.
[19] CIPOLLONE. F ,CHIARELLI. F. Enhanced soluble CD 40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activetion in patients with diabetes mellitus : effect of improved metabolic control ,Diabetologia 2005 ,48 (6):12161224.
[20] CIPOLLONE F,CHIARELLI F. Enhanced soluble CD 40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activetion in patients with diabetes mellitus : effect of improved metabolic control ,Diabetologia .2005 ;48 (6):12161224.
[21] KATAKAMI N , KENETO H , MATSUHISA M，et al .Association of so上一页 [1] [2] [3] [4] [5] [6] [7] 下一页
上一个医学论文： C反应蛋白及其多态性与冠心病
下一个医学论文： 抗凝血酶治疗弥散性血管内凝血的研究进展
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文